CARA - Cara Therapeutics EPS beats by $0.40 beats on revenue

Cara Therapeutics (NASDAQ:CARA): Q3 GAAP EPS of -$0.02 beats by $0.40. Revenue of $20.27M (+118.7% Y/Y) beats by $9.06M. Press Release Cash, cash equivalents and marketable securities at September 30, 2021 totaled $193.4 million compared to $251.5 million at December 31, 2020.  Financial Guidance: Based on timing expectations and projected costs for current clinical development plans, Cara expects that its existing unrestricted cash and cash equivalents and available-for-sale marketable securities as of September 30, 2021, including the milestone payments received in October 2021 of $65.0 million from Vifor and VFMCRP, will be sufficient to fund its currently anticipated operating expenses and capital expenditures through 2023, without giving effect to any additional potential milestone payments or potential product revenue under existing collaborations.

For further details see:

Cara Therapeutics EPS beats by $0.40, beats on revenue